Last reviewed · How we verify
Bosentan group
Bosentan is an endothelin receptor antagonist that works by blocking the action of endothelin-1, a potent vasoconstrictor.
Bosentan is an endothelin receptor antagonist that works by blocking the action of endothelin-1, a potent vasoconstrictor. Used for Pulmonary arterial hypertension.
At a glance
| Generic name | Bosentan group |
|---|---|
| Sponsor | Elpen Pharmaceutical Co. Inc. |
| Drug class | Endothelin receptor antagonist |
| Target | Endothelin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting endothelin-1, bosentan causes vasodilation and reduces pulmonary artery pressure, which is beneficial for patients with pulmonary arterial hypertension. This mechanism of action is specific to the endothelin receptor, which is overexpressed in the pulmonary arteries of patients with this condition.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Headache
- Dizziness
- Nausea
- Fatigue
Key clinical trials
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension (PHASE3)
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) (PHASE2)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
- BUILD 3: Bosentan Use in Interstitial Lung Disease (PHASE3)
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (PHASE4)
- Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH) (PHASE3)
- Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bosentan group CI brief — competitive landscape report
- Bosentan group updates RSS · CI watch RSS
- Elpen Pharmaceutical Co. Inc. portfolio CI